Jul 31, 2019 · Chimerix will develop Cantex Pharmaceuticals’ Phase III-bound CX-01 as a first-line treatment for Acute Myeloid Leukemia (AML) and possibly other blood cancers, through …

May 26, 2019 · CX-01 is a low anticoagulant heparin derivative that retains heparin’s ability to alter the activity of the CXCL12/CXCR4 axis, P-selectin, extracellular histones, and Platelet …

fester cr-nanotech cx-01 Mortero de fraguado instantáneo para obturación de salidas francas de agua, compuesto en polvo base cemento, agregados minerales de granulometría controlada y …

Dec 7, 2017 · We hypothesize that infusional CX-01 will disrupt the bone marrow microenvironment and increase the cytotoxic effects of azacitidine on MDS and AML …

Feb 2, 2018 · In a pilot study, the nonanticoagulant heparin derivative CX-01 was well tolerated when combined with chemotherapy for the treatment of AML. Preliminary results show …

Sep 19, 2018 · CX-01 is a low-anticoagulant heparin derivative that has been studied in the treatment of newly diagnosed AML as well as refractory MDS. In AML, relapses are common …

Dec 2, 2016 · We present here updated results of this study that combined the low anticoagulant heparin CX-01 with chemotherapy for the treatment of AML. Induction consisted of cytarabine …

Mar 21, 2025 · For the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia; The investigators hypothesize that CX-01 will disrupt the bone marrow …

May 21, 2021 · New data from the American Society of Clinical Oncology (ASCO) 2021 Meeting highlights the potential efficacy of CX-01, a low anticoagulant herapin derivative, for the …